Is this vaccine effective for everyone？ Once and for all after vaccination？
CCTV News:On May 30, the highly concerned HPV nine-valent vaccine (nine-valent cervical cancer vaccine) began to be injected in Boao, Hainan. On the first day of injection, about 1,000 people completed the vaccine appointment.
HPV vaccination should be treated rationally
A month ago (April 29th), National Medical Products Administration approved the marketing of nine-valent cervical cancer vaccine in the Mainland. Boao Lecheng International Medical Tourism Pioneer Zone enjoys nine supporting policies, such as drug import registration and approval, and it takes only one month to take the lead in completing all the approval of nine-valent cervical cancer vaccine for marketing injection, and injecting it for school-age women in need. According to the regulations,The vaccine in the Mainland is suitable for women aged 16 to 26.
It is understood that HPV nine-valent vaccine is the most comprehensive vaccine against HPV virus in the world, and it can prevent 90% of cervical cancer against nine subtypes. It can be injected in Hong Kong earlier, and a shot costs about HK$ 2,250.
Experts from National Medical Products Administration, Health and Health Commission and China CDC have recently answered questions related to vaccines.Experts said that HPV vaccination should be treated rationally.(For details, see: the vaccine that can prevent more than 90% of cervical cancer can be listed in China conditionally.)
Nine-valent HPV vaccine "conditionally approved for marketing"
Experts pointed out that at present, the nine-valent HPV vaccine that has been approved for import registration by priority review is conditionally approved for marketing. Shao Jie, reviewer of the Clinical Department of Biological Products of the National Drug Administration Center, said that conditional approval paid attention to the ethnic differences of clinical trial subjects.
Data from overseas clinical trials show that,There are more than 2,000 Asian people in the clinical trial of the nine-valent HPV vaccine.China, Hongkong, China, Taiwan Province, Japan, Korea, etc. The population of China, Hongkong and Taiwan Province, China, which were included in the clinical trial, were analyzed separately, and the results were consistent with those of the global population. This is the basis for the inclusion of imported nine-valent HPV vaccine in conditional approval.
Experts said that the overall principle of conditional approval is that the benefits outweigh the risks. After the enterprise is conditionally approved, it needs to improve the follow-up research work as required, and the regulatory agency will continue to follow up and supervise the vaccine throughout its life cycle.
The age range of vaccination adaptation is 16 ~26 years old.
The nine-valent HPV vaccine approved for marketing in ChinaThe age range of vaccination adaptation is 16 ~26 years old.. The reason why it is designated as this age group comes from three aspects:
1. At this age, the overseas clinical research data of the vaccine and its protective effect against persistent infection in East Asian population all suggest that the benefits outweigh the risks.
Second, the probability of sexual behavior among girls aged 9-15 in China is very low. However, the 9-to 15-year-old vaccinators only carried out the immune bridging test, and the clinical research data of the East Asian Chinese population in this test were limited.
Third, women over the age of 26 may have a history of virus exposure and infection. At present, there is no evidence to prove that this vaccine has a protective effect on the exposed population of this age group.
In addition, experts said that,The incidence of adverse reactions of nine-valent HPV vaccine will be higher than that of four-valent vaccine.
Wang Huaqing, chief expert of immunization program of China CDC, pointed out that vaccination is primary prevention and screening is secondary prevention, which are equally important at present.Cervical cancer screening measures should not be relaxed because of vaccination.
What are the differences between bivalent, tetravalent and ninth-order vaccines used to prevent cervical cancer? A picture makes it clear ↓
